Investor Relations

News Releases

 
News Releases
  Date Title View
Jul 17, 2017
Company Expects Total Revenue Growth of 23% to 26% for Q2 2017 BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today...
Jul 12, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2017 financial results after the close of the market on Wednesday, July 26, 2017 and to hold a conference call the next day, Thursday, July 27, 2017, at 9:00 a.m. E...
Jul 6, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D....
May 30, 2017
BEDFORD, Mass. & VIENNA--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to present Phase III data on CINGAL®, its nov...
May 25, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the enrollment of the first patient in its supplemental Phase III trial ev...
May 23, 2017
Ribbon-Cutting Ceremony Opens the Doors to State-of-the-Art Facility Built to Supply Global Demand for Anika's Extensive Commercial Portfolio of More than 20 Products and Technologies BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated ort...
May 22, 2017
Positive Data Provides Further Rationale for Strong and Growing Physician Demand for CINGAL following Commercial Launches in Europe and Canada BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company speci...
May 3, 2017
MONOVISC Revenue Increases 24% Year-over-YearTotal Revenue Grows 5% Year-over-YearCommercially Launches ORTHOVISC-T in Europe BEDFORD, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") t...
Apr 19, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call the next day, Thursday, May 4, 2017, at 9:00 a.m. ET to ...
Feb 28, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D.,...

= add release to Briefcase